CHEK - Check-Cap Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.1100
+0.0500 (+2.43%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close2.0600
Open2.0500
Bid2.1100 x 1800
Ask2.1200 x 1300
Day's Range2.0500 - 2.1394
52 Week Range1.2800 - 4.2000
Volume50,772
Avg. Volume70,419
Market Cap17.441M
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-1.8110
Earnings DateNov 05, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • Check-Cap Announces Positive Results from U.S. Pilot Study of C-Scan® System
    PR Newswire

    Check-Cap Announces Positive Results from U.S. Pilot Study of C-Scan® System

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and only preparation-free ingestible scanning capsule based system for the prevention of colorectal cancer through the detection of precancerous polyps, today announced positive results from the Company's pilot study of the C-Scan® System in the U.S.

  • Is Check-Cap Ltd. (CHEK) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is Check-Cap Ltd. (CHEK) Going To Burn These Hedge Funds ?

    How do we determine whether Check-Cap Ltd. (NASDAQ:CHEK) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]

  • Check-Cap Announces $4.75 Million Private Placement
    PR Newswire

    Check-Cap Announces $4.75 Million Private Placement

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and only preparation-free ingestible scanning capsule based system for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that the Company has entered into definitive agreements with certain investors to purchase approximately $4.75 million of its ordinary shares in a private placement.

  • What Kind Of Shareholder Owns Most Check-Cap Ltd. (NASDAQ:CHEK) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most Check-Cap Ltd. (NASDAQ:CHEK) Stock?

    The big shareholder groups in Check-Cap Ltd. (NASDAQ:CHEK) have power over the company. Institutions will often hold...

  • Check-Cap Reports Third Quarter 2019 Financial Results and Corporate Highlights
    PR Newswire

    Check-Cap Reports Third Quarter 2019 Financial Results and Corporate Highlights

    Successfully launched U.S. pilot study and reported positive final results from post-CE approval study of the C-Scan® System ISFIYA, Israel , Nov. 6, 2019 /PRNewswire/ --  Check-Cap Ltd. (the "Company" ...

  • Check-Cap to Present at the Dawson James 5th Annual Small Cap Growth Conference
    PR Newswire

    Check-Cap to Present at the Dawson James 5th Annual Small Cap Growth Conference

    ISFIYA, Israel , Oct. 24, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap Expands Leadership Team With Appointment of Dr. Vardit Segal as Vice President of Clinical Affairs
    PR Newswire

    Check-Cap Expands Leadership Team With Appointment of Dr. Vardit Segal as Vice President of Clinical Affairs

    ISFIYA, Israel , Sept. 25, 2019 /PRNewswire/ --  Check-Cap Ltd.  (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics ...

  • Check-Cap to Present at the H.C. Wainwright 21st Annual Global Investment Conference
    PR Newswire

    Check-Cap to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    ISFIYA, Israel , Sept. 3, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare
    PR Newswire

    Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare

    GE Healthcare facility in Chicago to support clinical investigation needs of the C-Scan® System in the U.S. ISFIYA, Israel , Aug. 19, 2019 /PRNewswire/ --  Check-Cap Ltd. (the "Company" or "Check-Cap") ...

  • Check-Cap Reports Second Quarter 2019 Financial Results and Corporate Highlights
    PR Newswire

    Check-Cap Reports Second Quarter 2019 Financial Results and Corporate Highlights

    Reported positive final results from post-CE approval study of the C-Scan® System ISFIYA, Israel , Aug. 7, 2019 /PRNewswire/ --  Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: ...

  • Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System
    PR Newswire

    Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System

    ISFIYA, Israel, July 9, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free capsule based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system. The study included 90 evaluable patients who either had known polyps or were considered to be of average risk.

  • Check-Cap Appoints Joshua (Shuki) Belkar as Vice President of Operations
    PR Newswire

    Check-Cap Appoints Joshua (Shuki) Belkar as Vice President of Operations

    Mr. Belkar Brings More Than 20 Years of Global Medical Device Experience, Including at Medtronic and Mazor Robotics ISFIYA, Israel , June 3, 2019 /PRNewswire/ --  Check-Cap Ltd. (the "Company" ...

  • Check-Cap to Present Data at Digestive Disease Week® Demonstrating Substantial Improvement in Precancerous Polyp Detection
    PR Newswire

    Check-Cap to Present Data at Digestive Disease Week® Demonstrating Substantial Improvement in Precancerous Polyp Detection

    ISFIYA, Israel , May 16, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap Reports First Quarter 2019 Financial Results
    PR Newswire

    Check-Cap Reports First Quarter 2019 Financial Results

    Initiates U.S. pilot study of C-Scan® at NYU School of Medicine and Mayo Clinic ISFIYA, Israel , May 13, 2019 /PRNewswire/ --  Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: ...

  • Check-Cap Announces Second Trial Site Joins Ongoing U.S. Pilot Study of C-Scan®
    PR Newswire

    Check-Cap Announces Second Trial Site Joins Ongoing U.S. Pilot Study of C-Scan®

    Mayo Clinic joins New York University in pilot study of C-Scan® in the U.S. ISFIYA, Israel, May 13,  2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that Mayo Clinic is the second trial site participating in the Company's ongoing pilot study of the C-Scan® system in the U.S.

  • Check-Cap Initiates U.S. Pilot Study of C-Scan® for Colorectal Cancer Screening
    PR Newswire

    Check-Cap Initiates U.S. Pilot Study of C-Scan® for Colorectal Cancer Screening

    ISFIYA, Israel, April 8, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced the initiation of its U.S. pilot study of the C-Scan® system, following Institutional Review Board (IRB) approval and full Investigational Device Exemption (IDE) application approval by the U.S. Food and Drug Administration (FDA). The first patients have ingested the C-Scan® capsule at the New York University School of Medicine. "The pilot study initiation is a critical milestone on our path for developing and potentially commercializing the C-Scan® system in the U.S.," said Alex Ovadia, chief executive officer of Check-Cap.

  • Check-Cap Reports Fourth Quarter and Full-Year 2018 Financial Results
    PR Newswire

    Check-Cap Reports Fourth Quarter and Full-Year 2018 Financial Results

    ISFIYA, Israel , March 28, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap Announces Appointment of Mira Rosenzweig as Chief Financial Officer
    PR Newswire

    Check-Cap Announces Appointment of Mira Rosenzweig as Chief Financial Officer

    ISFIYA, Israel , March 18, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (Nasdaq: CHEK) (Nasdaq: CHEKW), (Nasdaq: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap Announces Institutional Review Board Approval to Initiate U.S. Pilot Study of C-Scan®
    PR Newswire

    Check-Cap Announces Institutional Review Board Approval to Initiate U.S. Pilot Study of C-Scan®

    ISFIYA, Israel, Feb. 12, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW), (CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free capsule based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced it has received Institutional Review Board (IRB) approval from New York University School of Medicine to initiate a U.S. pilot study of the C-Scan® system. "We are excited to receive IRB approval as this important milestone enables Check-Cap to bring the C-Scan® system into the clinic in the U.S.," said Alex Ovadia, chief executive officer of Check-Cap.

  • Check-Cap Ltd. Announces Closing of $7.5 Million Registered Direct Offering
    PR Newswire

    Check-Cap Ltd. Announces Closing of $7.5 Million Registered Direct Offering

    ISFIYA, Israel, Feb. 7, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first and only preparation free capsule-based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced the closing of its previously announced registered direct offering with certain institutional investors for the purchase of 2,906,376 units, at a purchase price of $2.58 per unit. Each unit consisted of (i) one ordinary share (or ordinary share equivalent), and (ii) a warrant to purchase one half ordinary share.

  • Check-Cap Ltd. Announces $7.5 Million Registered Direct Offering
    PR Newswire

    Check-Cap Ltd. Announces $7.5 Million Registered Direct Offering

    ISFIYA, Israel, Feb. 4, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first and only preparation free capsule-based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that it has entered into definitive agreements with institutional investors for the purchase of 2,906,376 units, at a purchase price of $2.58 per unit, in a registered direct offering. Each unit consists of (i) one ordinary share (or ordinary share equivalent), and (ii) a warrant to purchase one half ordinary share.